It has been shown that EMT conferred to drug resistance of NSCLC (Thomson et al., 2005; Rho et al., 2009) and TGFβ is a pivotal driver of these multistep process (Hua et al., 2020). This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.